Recomgen

Beijing Recomgen Biopharma is a Chinese biotechnology company focused on the development and commercialization of recombinant protein therapeutics for rare diseases, specifically in the field of hematology. The company's lead product, FR701, is a recombinant human coagulation factor VIIa (rFVIIa) that received NMPA approval in 2023, making it the first domestically developed rFVIIa in China for treating hemophilia patients with inhibitors. Recomgen utilizes a sophisticated mammalian cell expression platform to produce high-quality biologics that aim to reduce China's reliance on imported blood-derived products. The company's pipeline includes several other recombinant coagulation factors, such as factor IX and factor VIII, currently in various stages of clinical and preclinical development. Headquartered in Beijing, Recomgen is backed by prominent venture capital firms and maintains integrated R&D and manufacturing capabilities.